Article Text

PDF

Review: β blockers increase fatigue and sexual dysfunction but not depression after myocardial infarction
  1. Alan C Swann, MD
  1. University Texas-Houston Medical School, Houston, Texas, USA

    Statistics from Altmetric.com

    
 
 QUESTION: In patients who have had myocardial infarction, heart failure, or hypertension, do β blockers increase depressive symptoms, fatigue, and sexual dysfunction?

    Data sources

    Studies were identified by searching Medline (1966–2001) with the keywords myocardial infarction, heart failure, or hypertension in combination with the keywords adrenergic β antagonists and trial; and by scanning reference lists.

    Study selection

    English language studies were selected if they were randomised controlled trials with a placebo comparison, were not crossover trials, enrolled ≥100 patients, and had ≥6 months of follow up.

    Data extraction

    Data were extracted on number of patients; presence of heart failure, hypertension, or myocardial infarction; length of follow up; type of β blocker; and patient reported adverse events (ie, depressive symptoms, fatigue, and sexual dysfunction).

    Main results

    15 studies (42 409 patients) were included. Follow up ranged from 6–59 months. β blockers led to an increase in fatigue (10 studies, 17 682 patients); no difference existed between β blockers and placebo for depressive symptoms (7 studies, 10 662 patients) or sexual dysfunction (6 studies, 14 897 patients) (table 1). Withdrawals because of fatigue (10 studies, 29 454 patients) and sexual dysfunction (4 studies, 11 260 patients) were higher in the β blocker group than in the placebo group; withdrawals for depressive symptoms did not differ between groups (4 studies, 5803 patients) (table 1).

    Table 1.

    β blockers v placebo in myocardial infarction at ≥6 months*

    Conclusions

    In patients who have had myocardial infarction, hypertension, or heart failure, β blockers increase fatigue and withdrawals because of fatigue or sexual dysfunction. β blockers do not increase depressive symptoms.

    Commentary

    β noradrenergic antagonists have broad utility, but they are considered to have troublesome side effects. Ko et al found that β blockers were associated with increased fatigue and increased withdrawal because of fatigue or sexual dysfunction. Yet, closer examination sheds doubt on whether the evidence supports differential effects across the 3 problems and raises questions about the interpretation of side effects in placebo controlled trials.

    Both placebo and active drug effects ranged widely across studies and were strongly correlated (table 2). The range across studies dwarfed the relatively small apparent differences between placebo and active drug. The significant difference between placebo and active drug for withdrawal because of fatigue or sexual dysfunction may reflect a true adverse effect of β blockers, although with sexual dysfunction the difference may not be meaningful because almost all withdrawals were in the same study.

    Table 2.

    Adverse effects of β blockers

    The heterogeneity across trials, with close tracking of placebo and active drug effects, is consistent with a nocebo effect, whereby negative expectations can result in unfavorable outcomes.1 Side effects of placebo have been documented to resemble those of the reference drug.2 Patients in randomised clinical trials receive detailed information about potential side effects of the reference drug. This contributes to similar “side effect” rates for active drug and placebo but would not account for the wide range of event rates. Such a range could result from varying sources, including patient characteristics, actual β blockers used, or study design.

    In summary, a prominent apparent nocebo effect probably biases toward underdetection of side effects in placebo controlled trials. Furthermore, the studies were so heterogeneous in event rates that it is difficult to interpret their results in combination. Even with these biasing factors, differences in the incidence of fatigue and sexual dysfunction emerge.

    References

    View Abstract

    • .

      Additional Comments

      Reply to Dr Swann (commentator) by the original authors, Ko et al.

      Response from Dr Swann to the reply

      Files in this Data Supplement:

    Footnotes

    • Source of funding: not stated.

    • For correspondence: Dr H M Krumholz, Yale University School of Medicine, New Haven, CT, USA. harlan.krumholz{at}yale.edu

    • Abstract and commentary also published in ACP Journal Club

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.